Oman Pharmaceuticals & Healthcare Report

Published 23 December 2014

  • 102 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Oman Pharmaceuticals & Healthcare Report

BMI View: The Omani government is placing an increasing emphasis on the healthcare sector , demonstrated by a large increase in funding for the 2015 national budget . M uch of this investment is allocated to building state-of-the-art healthcare infrastructure in an attempt to promote the medical tourism industry. We highlight continuing commercial opportunities in the Omani pharmaceutical market for multinational drugmakers due to the high penetration of patented medicines, lack of local competition and the development of the private healthcare sector.

Headline Expenditure Projections

  • Pharmaceuticals: OMR187mn (USD487mn) in 2013 to OMR200mn (USD518mn) in 2014; 6.6% in local currency and US dollar terms. Forecast broadly in line with Q414.

  • Healthcare: OMR831mn (USD2.16bn) in 2013 to OMR891mn (USD2.31bn) in 2014; +7.2% in local currency and US dollar terms. Forecast unchanged from Q414.

Risk/Reward Index

Oman has limited longer-term commercial potential due to its small population and the fact that the government is responsible for the bulk of healthcare costs, which will increase the need for cost containment in the coming years. In Q115, Oman's Pharmaceutical Risk/Reward Index (RRI) scores 49.3 out of 100, which has seen the country maintain its position in 10th place in the Middle East and Africa matrix out of 31 countries.

Key Trends And Developments

  • The Burjeel Medical Centre was inaugurated in Muscat in October 2014, offering speciality treatment services including internal and family medicine, paediatrics, obstetrics and gynaecology, ophthalmology, general surgery, dental medicine, orthopaedics, cardiology, ENT and dermatology.

  • A visiting Indian business delegation of hospitals, healthcare institutes and pharmaceutical companies visited Muscat in September 2014 with the view to expanding into Oman's healthcare sector.

  • In September 2014, it was announced that the Ministry of Health in Oman will support private sector hospitals to upgrade...

Table of Contents

BMI Industry View
7
SWOT
10
Political
12
Economic
13
Business Environment
14
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Oman 2010-2018)
16
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2010-2018)
18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2010-2018)
18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2010-2018)
19
Prescription Drug Market Forecast
20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Oman 2010-2018)
21
Patented Drug Market Forecast
22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Oman 2010-2018)
22
Generic Drug Market Forecast
23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Oman 2010-2018)
24
OTC Medicine Market Forecast
25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Oman 2010-2018)
26
Pharmaceutical Trade Forecast
27
Table: Pharmaceutical Trade Data And Forecasts (Oman 2012-2018)
28
Table: Pharmaceutical Trade Data And Forecasts local currency (Oman 2012-2018)
28
Other Healthcare Data
29
Key Risks To BMI's Forecast Scenario
30
Macroeconomic Forecasts
31
Economic Analysis
31
Table: Economic Activity (Oman 2009-2018)
38
Industry Risk Reward Ratings
39
Middle East & Africa Risk/Reward Index
39
Oman Risk/Reward Ratings
46
Rewards
46
Risks
47
Market Overview
48
Industry Trends And Developments
49
Industry Trends And Developments
49
Epidemiology
49
Communicable Diseases
49
Non-Communicable Diseases
50
Healthcare Sector
51
Public Healthcare Sector Developments
54
Private Healthcare Sector Developments
56
Table: Number Of Health Centres In Oman By Region
58
Table: Number And Type Of Health Institutions In Oman In 2012
59
Healthcare Insurance
59
Telemedicine
61
Medical Tourism
61
Research And Development
63
Clinical Trials
64
Regulatory Development
66
Regulatory Developments
67
Intellectual Property Regime
67
Regional Harmonisation
68
Pricing And Reimbursement Regime
69
Competitive Landscape
73
Domestic Pharmaceutical Industry
73
Foreign Pharmaceutical Industry
74
Pharmaceutical Distribution
75
Company Profile
76
Zynova/Oman Pharmaceutical Products Company
76
National Pharmaceutical Industries (NPI)
79
Novartis
82
GlaxoSmithKline
85
Sanofi
86
Johnson & Johnson
88
Demographic Forecast
90
Table: Oman's Population By Age Group, 1990-2020 ('000)
91
Table: Oman's Population By Age Group, 1990-2020 (% of total)
92
Table: Oman's Key Population Ratios, 1990-2020
93
Table: Oman's Rural And Urban Population, 1990-2020
93
Glossary
94
Methodology
96
Pharmaceutical Expenditure Forecast Model
96
Healthcare Expenditure Forecast Model
96
Notes On Methodology
97
Risk/Reward Ratings Methodology
98
Ratings Overview
99
Table: Pharmaceutical Risk/Reward Ratings Indicators
99
Indicator Weightings
100

The Oman Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Oman Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Oman pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Oman, to test other views - a key input for successful budgeting and strategic business planning in the Omani pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Omani pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Oman.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc